News

  1. Virpax Pharmaceuticals Selects Kindeva Drug Delivery As Development Partner For Diclofenac pMDI Commercialization 4/27/2022

    Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) and Kindeva Drug Delivery will work together to advance the clinical program of the Virpax-developed Diclofenac topical spray film (Epoladerm™) in the United States.

  2. Mithra CDMO Announces Collaboration With MedinCell For The Development Of Injectable Products For Malaria And Transplant Rejection 4/26/2022

    Mithra today announced a collaboration with MedinCell for the development of two long-acting injectable products in its CDMO based in Liège

  3. Dutch CDMO BioConnection Announces Substantial Investment By Gimv, Supported By Existing Shareholders 4/22/2022

    BioConnection, an independent CDMO (Contract Development Manufacturing Organization) based in Oss, The Netherlands, specialized in GMP-certified manufacturing of sterile drug products in vials and syringes, today announced the completion of a new capital raising led by the European investment company Gimv, and supported by existing shareholders Pharming Group N.V., Mibiton and BioConnection's own management

  4. INCOG BioPharma Completes Construction Of Cleanrooms, On Track To Manufacture Injectable Drug Products In Q3 2022 4/5/2022

    INCOG BioPharma Services, an Indiana-based contract development and manufacturing organization (CDMO) reached another major milestone in its facility by completing the construction of its cleanroom production area within the new 90,000 sq. ft. bio/pharmaceutical manufacturing site.

  5. Viatris Inc. Announces Receipt Of The First FDA Approval For Generic Version Of Symbicort® Inhalation Aerosol, Breyna™ (Budesonide And Formoterol Fumarate Dihydrate Inhalation Aerosol), In Partnership With Kindeva 3/16/2022

    Viatris Inc. and Kindeva Drug Delivery announced that, Mylan Pharmaceuticals Inc., a Viatris subsidiary, has received approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for BreynaTM (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), the first approved generic version of AstraZeneca’s Symbicort®.

  6. Sanofi Announces €300 Million Collaboration With Blackstone Life Sciences To Advance An Innovative Treatment For Multiple Myeloma 3/15/2022

    Sanofi and Blackstone (NYSE: BX) today announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences (BXLS) will contribute up to €300 million to accelerate the global pivotal studies and the clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa®, to treat patients with multiple myeloma (MM).

  7. INCOG BioPharma Services Completes Analytical And Quality Control Testing Laboratory & Technology Transfer Suite 3/1/2022

    The newly designed analytical chemistry and microbiology laboratories will provide a wide range of essential biological and chemical testing capabilities to support sterile injectable drug product fulfillment programs, including sterility testing.

  8. Alcami Adds Additional Formulation Development Capabilities 3/1/2022

    Alcami, a U.S.-based pharmaceutical contract development and manufacturing organization (CDMO), announced today the addition of a 3,800 ft² Non-GMP Formulation Development Laboratory (FDL). The dedicated Non-GMP formulation development space, which is co-located within the same facility as Alcami's parenteral manufacturing operation that offers four isolator filling lines for liquid and lyophilized products, is ready to support customers with Preclinical and Clinical development programs.

  9. CDMO Recro Adds New Filling And Lyophilization Equipment To Meet Industry's Needs 2/24/2022

    Recro Pharma, Inc., a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported key progress in adding fill/finish and lyophilization capabilities to its broad suite of CDMO offerings. All construction and equipment installation related to this service expansion has been completed at the company’s San Diego facility and final validation and commissioning activities are underway.

  10. Kindeva Drug Delivery To Manufacture New, Greener Inhalers At UK Manufacturing Site To Help Cut Carbon Emissions 2/16/2022

    One of the UK’s biggest asthma inhaler manufacturers has today announced its intention to invest in its UK manufacturing site to support the development of a new generation of greener inhalers, designed to help support the National Health Service (NHS) to cut a contributor to its emissions.